We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Following the June update that allowed for a lower dose ...

Postexposure prophylaxis with bamlanivimab plus etesevimab is not a substitute for vaccination against COVID-19. The Food and Drug Administration (FDA) has expanded the Emergency Use Authorization ...

In a study conducted at the University of Washington, USA, the researchers assert that post-exposure prophylaxis with monoclonal antibodies could improve the clinical outcomes and health system costs ...

In a recent study posted to the medRxiv* preprint server, researchers determined evidence for post-exposure vaccination in reducing the mortality rate of coronavirus disease 2019 (COVID-19).

Ensitrelavir significantly reduced the likelihood of developing symptomatic COVID-19 following household exposure compared with placebo. Treatment with ensitrelvir was found to prevent symptomatic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A single subcutaneous dose of Regeneron’s antibody ...

Heavy is the head that wears the COVID-19 crown. Late last week, Pfizer revealed its antiviral Paxlovid fell short in a post-exposure protection trial. Still, in the pill’s quest to reach as many ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral ...

(RTTNews) - Swiss drug maker Roche Group (RHHBY) announced Tuesday that the U.S. Food and Drug Administration has approved a supplemental New Drug Application or sNDA for Xofluza (baloxavir marboxil) ...